Comirnaty (Pfizer-BioNTech COVID-19 Vaccine): mRNA shot remains a key option for booster protection

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 11:57:05 AM ET. Details in the imprint.

Comirnaty, the Pfizer-BioNTech COVID-19 Vaccine, remains one of the most widely used mRNA-based COVID-19 vaccines worldwide and continues to serve as a primary booster option in the United States. The current US formulation is an updated monovalent vaccine targeting circulating SARS-CoV-2 variants in line with recommendations from the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). In the US, the vaccine is generally available at no out-of-pocket cost for many people through insurance coverage or federal programs, although specific access conditions can vary. For adult consumers and families, Comirnaty is positioned as a familiar, extensively studied option for ongoing COVID-19 protection.

What Comirnaty is and how the current formulation works

Comirnaty is an mRNA vaccine that delivers a piece of genetic code instructing cells to produce a version of the SARS-CoV-2 spike protein, which then prompts the immune system to generate antibodies and cellular responses. Unlike traditional vaccines based on inactivated or protein subunit platforms, mRNA vaccines do not contain live virus and do not interact with or alter human DNA. The mRNA in Comirnaty is encapsulated in lipid nanoparticles that protect the fragile genetic material and help it enter cells, where it is translated into spike protein before being rapidly broken down.

The currently authorized US formulation is an updated monovalent vaccine aligned with variant recommendations from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which has moved toward strain selection in a way similar to seasonal influenza vaccines. For the 2024-2025 season, for example, US regulators recommended an Omicron JN.1-lineage-based monovalent composition, and Pfizer-BioNTech announced that their updated Comirnaty formulation was developed to match that guidance. Public health agencies emphasize that updated mRNA vaccines like Comirnaty are designed to restore protection that may wane over time and to broaden immunity against currently circulating strains.

Clinical studies and real-world effectiveness data have repeatedly shown that the Pfizer-BioNTech mRNA vaccine reduces the risk of symptomatic COVID-19, severe disease, hospitalization, and death, especially in older adults and those with underlying conditions. In earlier Omicron waves, booster doses of mRNA vaccines, including Comirnaty, were associated with substantially lower rates of hospitalization compared with being unvaccinated or only having the primary series, according to data summarized by the CDC. While variant evolution has made preventing all infections more challenging, the main public-health goal of updated boosters is to preserve protection against severe outcomes.

Dosing, eligibility, and US availability for consumers

In the United States, Comirnaty is authorized and approved in multiple age-specific formulations, with different dose strengths and volumes for adults, adolescents, and younger children. For people ages 12 years and older, the current updated monovalent formulation of the Pfizer-BioNTech COVID-19 Vaccine is given as a single intramuscular injection in the deltoid muscle when used as a booster dose, typically at least several months after the previous COVID-19 vaccine dose, in line with CDC schedules. Children ages 5 to 11 years receive a lower-dose formulation, while younger children have tailored pediatric doses and multi-dose vials, and US healthcare providers are instructed to follow age-appropriate dosing tables.

CDC recommendations for 2025-2026 and beyond continue to prioritize updated doses for adults ages 65 and older, individuals with moderate or severe immunocompromise, and others at higher risk of serious COVID-19, while still allowing other adults to receive a booster if they choose to do so. For many healthy adults under 65, a single updated dose per season may be adequate, but immunocompromised patients may be advised to receive additional doses after consultation with their healthcare providers. Because guidance evolves with new data, consumers are consistently advised to check the latest CDC and FDA information or consult physicians or pharmacists before scheduling a vaccination.

From an access standpoint, Comirnaty is widely available in the US through retail pharmacies, health-system clinics, and some primary-care practices. Major pharmacy chains advertise online appointment scheduling for the updated Pfizer-BioNTech COVID-19 Vaccine, which makes it relatively straightforward for individuals to book a slot close to home. For many people with private insurance, Medicare, or Medicaid, the vaccine is covered with no copay, and the CDC’s Bridge Access Program has provided a pathway for some uninsured adults to receive no-cost COVID-19 vaccines at participating locations. As public financing evolves, consumers may increasingly encounter list prices, but many US vaccination sites continue to bill insurers directly without out-of-pocket charges at the point of care.

Safety profile, side effects, and regulatory oversight

Comirnaty has been administered to hundreds of millions of people worldwide since its initial emergency authorization in late 2020, giving regulators a large safety dataset compared with many newer vaccines. Common side effects are typically mild to moderate and short-lived, including pain at the injection site, fatigue, headache, muscle pain, chills, joint pain, and fever, most often resolving within a few days. These reactions are signs of immune activation and are similar to those reported with many other adult vaccines.

Regulators and public-health agencies have also highlighted rare but important risks associated with mRNA COVID-19 vaccination, including myocarditis and pericarditis, especially in adolescent and young adult males after the second dose. According to data summarized by the CDC and FDA, these heart inflammation events remain rare, cases are usually mild, and most patients respond well to treatment and rest, but clinicians are advised to monitor symptoms such as chest pain, shortness of breath, or palpitations after vaccination. Ongoing post-marketing surveillance, including the Vaccine Adverse Event Reporting System (VAERS) and other safety databases, continues to track adverse events and guide updates to product labeling and usage recommendations.

The US FDA initially granted Comirnaty emergency use authorization and then full Biologics License Application (BLA) approval for certain age groups. As the regulatory framework matured, the Pfizer-BioNTech COVID-19 Vaccine family has seen multiple label and formulation updates, including the move from original and bivalent compositions to updated monovalent formulations targeting currently dominant variants. Product information documents published by Pfizer and BioNTech describe composition, manufacturing standards, stability conditions, and storage requirements, including the use of ultra-cold or frozen storage for certain presentations before thawing and dilution.

How Comirnaty fits into BioNTech’s broader portfolio

Comirnaty remains the only BioNTech co-developed product with large-scale commercial sales, even as the company transitions toward its oncology pipeline as a future growth engine. During the COVID-19 pandemic, revenues from the Pfizer-BioNTech COVID-19 Vaccine formed the overwhelming majority of BioNTech’s income, generating many billions of euros and enabling a sizable cash position and investment capacity. More recently, BioNTech has guided investors to expect significantly lower COVID-19 vaccine revenue compared with peak pandemic years, reflecting a shift from mass primary-series campaigns to seasonal booster markets.

At the same time, BioNTech is using the scientific and regulatory experience gained with Comirnaty to support next-generation mRNA vaccine programs, including projects targeting influenza, combination respiratory vaccines, and individualized cancer vaccines. The company’s mRNA platform, lipid nanoparticle technology, large-scale manufacturing infrastructure, and global regulatory relationships, all sharpened during the rapid development of Comirnaty, are now being applied beyond COVID-19. For consumers, that means the Pfizer-BioNTech COVID-19 Vaccine is not only a standalone booster option but also an early example of a platform that could yield additional preventive and therapeutic products over the coming years.

Against this backdrop of declining but still meaningful COVID-19 vaccine demand, Comirnaty continues to contribute to BioNTech’s revenue base while the company prepares to seek regulatory approval for its first oncology products. Shares of BioNTech SE (US09075V1026, ticker BNTX) traded at $89.52 on Nasdaq on June 12, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.